Just noticed Guggenheim put out a fresh analyst coverage on Cullinan Therapeutics (CGEM) recently with a Buy recommendation. Pretty interesting timing given the stock moves. Their price target is sitting at $33.15, which would suggest something like 160% upside from where it was trading around $12.73. Not sure if that holds up now, but the recommendation definitely caught some attention.

What's more interesting to me is the fund positioning. There are about 258 institutional investors holding positions in CGEM, though that's actually down from last quarter. The big holders seem to be MPM Oncology Impact Management with roughly 13% of the company, and Lynx1 Capital with close to 10%. Some funds like Deerfield Management have actually trimmed their positions pretty significantly - down over 30% in their holdings.

The put/call ratio is sitting at 0.44 which leans bullish. Still, it's worth watching how institutions move after this analyst recommendation. Sometimes that's a good signal, sometimes not.